Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Chia-Yu
CY
Chu
Chih-Hsin
CH
Yang
Hsien-Ching
HC
Chiu
D000230:Adenocarcinoma / Q000188:drug therapy; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000077143:Docetaxel; D003875:Drug Eruptions / Q000209:etiology*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects*; D004890:Erythema / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives*; D010292:Paresthesia / Q000139:chemically induced*; D012867:Skin / Q000473:pathology; D043823:Taxoids; D000093542:Gemcitabine
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D017239:Paclitaxel; D000093542:Gemcitabine